Hyperuricemia and gout: eminently treatable disorders
Lindsley, H.B.
Journal of the Kansas Medical Society 79(11): 614-617
1978
ISSN/ISBN: 0022-8699 PMID: 712185 Document Number: 131153
Document emailed within 1 workday
Related Documents
Roux, H.; Vovan, L.; Dutertre, P.; Serratrice, G.; Recordier, A.M. 1972: Lipid disorders in gout and in hyperuricemia with myalgia Marseille Medical 109(10): 609-625Ferguson, A. 1997: Celiac disease, an eminently treatable condition, may be underdiagnosed in the United States American Journal of Gastroenterology 92(8): 1252-1254
Peuke, C. 2010: Hyperuricemia/gout Medizinische Monatsschrift für Pharmazeuten 33(11): 429-432
Hosoya, T. 2008: Gout and hyperuricemia: Introduction Nihon rinsho. Japanese journal of clinical medicine 66(4): 621-623
Roddy, E. 2008: Hyperuricemia, gout, and lifestyle factors Journal of Rheumatology 35(9): 1689-1691
Deray, G.; Assogba, U.; Le Hoang, P.; Brillet, G.; Baumelou, B.; Ben Hmida, M.; Jacobs, C. 1990: Cyclosporin induced hyperuricemia and gout Clinical Nephrology 33(3): 154
Richette, P.; Brière, C.; Hoenen-Clavert, V.; Loeuille, D.; Bardin, T. 2007: Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study Journal of Rheumatology 34(10): 2093-2098
Imanishi, M.; Ikegami, M.; Ishii, T.; Nishioka, T.; Uemura, T.; Kunikata, S.; Kanda, H.; Matsuura, T.; Akiyama, T.; Kurita, T. 1990: Clinical studies on hyperuricemia and gout after transplantation Hinyokika Kiyo. Acta Urologica Japonica 36(8): 893-896
Stĕpán, J.; Sváb, V.; Kolár, J.; Susta, A.; Cáp, F. 1983: The spine and polytopic hyperostoses in gout and hyperuricemia Der Radiologe 23(8): 371-374
Matulis, A.A.; Bareĭkene, I.P.; Venalis, A.I. 1987: Use of sorption for the correction of hyperuricemia in the combined treatment of gout Terapevticheskii Arkhiv 59(12): 17-19
Gall, E.P. 1979: Hyperuricemia and gout. A modern approach to diagnosis and treatment Postgraduate Medicine 65(4): 163-7 170 172
Kohkhar, N. 1980: Hyperuricemia and gout in secondary polycythemia due to chronic obstructive pulmonary disease Journal of Rheumatology 7(1): 114-116
Fadieieva, A.; Prystupa, L.; Pogorelova, O.; Kirichenko, N.; Dudchenko, I. 2016: Role of Slc2a9 and Abcg2 Gene Polymorphisms in Origin of Hyperuricemia and Gout Georgian Medical News 252: 79-83
Mangini, R.J. 1979: Drug therapy reviews: pathogenesis and clinical management of hyperuricemia and gout American Journal of Hospital Pharmacy 36(4): 497-504
Robles Gil, J.; Armas, C. 1978: Various epidemiological aspects of hyperuricemia and gout in Mexico: incidence and the cardiovascular risk factor Archivos del Instituto de Cardiologia de Mexico 48(6): 1121-1141
Ohno, I.; Okabe, H.; Yamaguchi, Y.; Saikawa, H.; Uetake, D.; Hikita, M.; Gomi, H.; Ichida, K.; Hosoya, T. 2008: Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol Nihon Jinzo Gakkai Shi 50(4): 506-512
Matzkies, F. 1983: Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone Fortschritte der Medizin 101(20): 953-959
Iwatani, M.; Nishioka, K. 1991: The prognosis of gout and hyperuricemia--the effect of the treatment on prognosis Nihon Rinsho. Japanese Journal of Clinical Medicine 49(5): 1124-1130
Turpin, G. 1983: Metabolic disorders in hyperuricemia La Revue du Praticien 33(43): 2271-2280
Frank, O. 1974: Investigations concerning the incidence of disorders of lipid and carbohydrate metabolism in primary gout and symptomless hyperuricaemia Wiener Klinische Wochenschrift 86(9): 252-256